Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance and Otsuka Pharmaceutical to Collaborate on PGx Study of Drug Response

NEW YORK, Sept. 21 (GenomeWeb News) - Genaissance Pharmaceuticals will conduct genotyping studies for Otsuka Pharmaceutical of Japan, the companies said today.


Under the research collaboration, New Haven, Conn.-based Genaissance will apply its HAP technology to identify genetic markers related to drug response. Both companies will own intellectual property resulting from the collaboration and will be eligible for royalties on revenues from diagnostic products that come out of the project.


The Otsuka Pharmaeutical Group, based in Tokyo, comprises 73 companies with 23,000 employees and has $4.4 billion in annual revenues.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.